766 related articles for article (PubMed ID: 28152480)
1. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
[TBL] [Abstract][Full Text] [Related]
2. High expression level of Tra2-β1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice.
Chen YC; Chang JG; Jong YJ; Liu TY; Yuo CY
PLoS One; 2015; 10(3):e0120721. PubMed ID: 25781985
[TBL] [Abstract][Full Text] [Related]
3. hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1.
Hofmann Y; Wirth B
Hum Mol Genet; 2002 Aug; 11(17):2037-49. PubMed ID: 12165565
[TBL] [Abstract][Full Text] [Related]
4. Targeting SR proteins improves SMN expression in spinal muscular atrophy cells.
Wee CD; Havens MA; Jodelka FM; Hastings ML
PLoS One; 2014; 9(12):e115205. PubMed ID: 25506695
[TBL] [Abstract][Full Text] [Related]
5. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
6. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
[TBL] [Abstract][Full Text] [Related]
7. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).
Hofmann Y; Lorson CL; Stamm S; Androphy EJ; Wirth B
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9618-23. PubMed ID: 10931943
[TBL] [Abstract][Full Text] [Related]
8. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Shababi M; Glascock J; Lorson CL
Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
[TBL] [Abstract][Full Text] [Related]
9. Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.
Dominguez CE; Cunningham D; Venkataramany AS; Chandler DS
Hum Genet; 2022 Feb; 141(2):239-256. PubMed ID: 35088120
[TBL] [Abstract][Full Text] [Related]
10. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.
Zhang ML; Lorson CL; Androphy EJ; Zhou J
Gene Ther; 2001 Oct; 8(20):1532-8. PubMed ID: 11704813
[TBL] [Abstract][Full Text] [Related]
11. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
[TBL] [Abstract][Full Text] [Related]
12. Is RNA manipulation a viable therapy for spinal muscular atrophy?
Horne C; Young PJ
J Neurol Sci; 2009 Dec; 287(1-2):27-31. PubMed ID: 19758605
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model.
Bebee TW; Dominguez CE; Samadzadeh-Tarighat S; Akehurst KL; Chandler DS
Hum Mol Genet; 2012 Oct; 21(19):4301-13. PubMed ID: 22763238
[TBL] [Abstract][Full Text] [Related]
16. Effects of Inhibitors of SLC9A-Type Sodium-Proton Exchangers on
Kanda S; Moulton E; Butchbach MER
Mol Pharmacol; 2022 Aug; 102(2):92-105. PubMed ID: 35667685
[TBL] [Abstract][Full Text] [Related]
17. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2.
Cartegni L; Hastings ML; Calarco JA; de Stanchina E; Krainer AR
Am J Hum Genet; 2006 Jan; 78(1):63-77. PubMed ID: 16385450
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
19. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy.
Pedrotti S; Bielli P; Paronetto MP; Ciccosanti F; Fimia GM; Stamm S; Manley JL; Sette C
EMBO J; 2010 Apr; 29(7):1235-47. PubMed ID: 20186123
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
